Other recent in vitro experiments have revealed that RGS16 is oversaturated in glioma cell lines and facilitates tumor cell proliferation and migration through the EMT process, suggesting the potential of RGS16 as a novel prognostic biomarker and therapeutic target (Huang et al., 2020). This evidence concerns the gene RGS16 and central nervous system cancer.